ZTR is a Potent Oral Kinase CDK9/2/5/7 inhibitor that readily crosses the Blood Brain Barrier(BBB)。 ZTR demonstrates strong efficacy in recurrent High-grade glioma (rHGG) and Diffuse intrinsic pontine glioma (DIPG). In recent days, we are in preparing process of registration two Phase 2 clinicaltrails of the above indications in US.
CDK9 inhibition MOA
ZTR depletes MYC levels,lowering glucose metabolism to stunt tumor formation and growth
oMitigate the effect of mutant IDH on the oncogenic process
Indications
recurrent High-grade glioma (rHGG)
Most common and aggressive forms of malignant brain tumor
Incidence of ~45K patients in the US, EU, and JPN
Specifically Supportive IDH Mutant as an Enriched Population
Diffuse intrinsic pontine glioma (DIPG)
Paediatric brainstem glioma，a leading cause of childhood cancer-related deaths.
~1650 pts in the US and EU1-3,age of onset 5-7 years old
Inoperable and TMZ-resistant, no treatments beyond radiation
京公网安备 11011402013345号
400-164-8199
zkbymed
zkby@zkbymed.com